Published in Circulation on February 01, 1991
Endothelin receptors mediating functional responses in human small arteries and veins. Br J Pharmacol (1994) 1.14
Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training. Heart Fail Rev (2008) 1.09
A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J (2013) 1.06
Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man. Br J Clin Pharmacol (2001) 0.95
Endothelin. Pharmacol Rev (2016) 0.95
The role of nitric oxide in the regional vasodilator effects of endothelin-1 in the rat. Br J Pharmacol (1992) 0.92
Endothelin-1, aging and hypertension. Curr Opin Cardiol (2008) 0.88
Repeatability of local forearm vasoconstriction to endothelin-1 measured by venous occlusion plethysmography. Br J Clin Pharmacol (2002) 0.85
Interaction between endothelin and vasodilators in the human internal mammary artery. Br J Clin Pharmacol (1994) 0.85
Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br J Pharmacol (2014) 0.85
An eicosanoid-centric view of atherothrombotic risk factors. Cell Mol Life Sci (2012) 0.84
Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardiovasc Drugs Ther (1995) 0.83
Local antinociception induced by endothelin-1 in the hairy skin of the rat's back. J Pain (2009) 0.83
Role of endothelin in the control of peripheral vascular tone in human hypertension. Heart Fail Rev (2001) 0.82
Modulation of endothelin-1-induced contractions by magnesium/calcium in porcine ciliary arteries. Graefes Arch Clin Exp Ophthalmol (1998) 0.81
Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched? Heart Fail Rev (2001) 0.78
Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle. Drugs (1993) 0.76
The renin-angiotensin-aldosterone system and cardiac ischaemia. Heart (1996) 0.76
Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension. Heart Fail Rev (2001) 0.75
Hemodynamic effects of bosentan in patients with chronic heart failure. Heart Fail Rev (2001) 0.75
Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem (1999) 6.59
Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med (1972) 4.80
Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation (1995) 4.59
Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med (1972) 3.73
Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation (2001) 3.38
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation (1996) 3.28
Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med (2000) 3.09
Acute heart transplant rejection due to Saint John's wort. Lancet (2000) 2.71
Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation (1994) 2.69
Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest (1990) 2.61
High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation (1997) 2.51
Impacted cancellous allografts and cement for revision total hip arthroplasty. J Bone Joint Surg Br (1993) 2.33
Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension (1986) 2.30
Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation (1998) 2.27
Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. Circulation (1992) 2.15
Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation (1996) 2.05
Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol (1975) 2.00
Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation (1990) 1.98
Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation (1991) 1.96
Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation (2000) 1.93
Detection of coronary artery disease by magnetic resonance myocardial perfusion imaging with various contrast medium doses: first European multi-centre experience. Eur Heart J (2004) 1.76
Decreased Beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension. Hypertension (1980) 1.69
Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation (1997) 1.67
Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest (1998) 1.62
Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med (1986) 1.60
Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol (1998) 1.58
Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation. Clin Pharmacol Ther (1982) 1.51
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J Clin Invest (1996) 1.50
Boneloc--The Christiansen experience revisited. Acta Orthop Scand (1995) 1.48
Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension (1990) 1.47
Fibromuscular hyperplasia: extension of the disease and therapeutic outcome. Results of the University Hospital Zurich Cooperative Study on Fibromuscular Hyperplasia. Nephron (1986) 1.47
Predictors of long-term survival after valve replacement for chronic aortic regurgitation; is M-mode echocardiography sufficient? Eur Heart J (2001) 1.47
Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci U S A (2000) 1.47
Endothelin. Key to coronary vasospasm? Circulation (1991) 1.46
Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart (2007) 1.45
Changes of immunoregulatory cells induced by psychological and physical stress: relationship to plasma catecholamines. Clin Exp Immunol (1984) 1.45
Aging, serum estradiol levels, and pregnancy differentially affect vascular reactivity of the rat uterine artery. J Soc Gynecol Investig (2000) 1.44
Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol (2000) 1.43
Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation (1990) 1.42
Biocompatibility of polyoxymethylene (Delrin) in bone. Biomaterials (1993) 1.41
Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension (1997) 1.41
Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. Arterioscler Thromb Vasc Biol (2001) 1.40
Calcium channels in thrombin-activated human platelet membrane. Nature (1988) 1.39
Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc Res (1999) 1.39
[Insulin--a side issue or indeed the cause of hypertension?]. Dtsch Med Wochenschr (1991) 1.39
[Effect of medicamentous cholesterol control on resources utilization in public health--significance of the Scandinavian Simvastatin Survival Study (4-S Study) for cost control in Swiss health management conditions]. Schweiz Med Wochenschr (1997) 1.39
Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res (1990) 1.37
Expression of tenascin by vascular smooth muscle cells. Alterations in hypertensive rats and stimulation by angiotensin II. Am J Pathol (1992) 1.36
Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res (2001) 1.36
Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation (2000) 1.35
Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest (1995) 1.34
Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension (1995) 1.34
Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy. N Engl J Med (1984) 1.34
Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells. Biochem Biophys Res Commun (1988) 1.32
The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology? Surv Ophthalmol (1995) 1.32
Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension (1987) 1.30
Different activation of L-arginine pathway by bradykinin, serotonin, and clonidine in coronary arteries. Am J Physiol (1990) 1.28
Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (1998) 1.26
Compliance in hypertension: facts and concepts. J Hypertens Suppl (1985) 1.25
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation (2001) 1.23
Induction of growth-related metabolism in human vascular smooth muscle cells by low density lipoprotein. J Biol Chem (1989) 1.23
Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation (1997) 1.22
Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation (1998) 1.20
Endothelium-dependent responses in carotid and renal arteries of normotensive and hypertensive rats. Hypertension (1988) 1.19
Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci (1992) 1.19
Activation of phospholipase A2 by endothelin in cultured vascular smooth muscle cells. Biochem Biophys Res Commun (1989) 1.18
Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation (1999) 1.18
Connective tissue growth factor. Friend or foe? Arterioscler Thromb Vasc Biol (1997) 1.17
Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension (1996) 1.16
Activation of human peripheral monocytes by angiotensin II. FEBS Lett (1994) 1.16
Femoral impaction bone grafting with the Exeter stem - the Swedish experience: survivorship analysis of 1305 revisions performed between 1989 and 2002. J Bone Joint Surg Br (2009) 1.15
Dark chocolate improves endothelial and platelet function. Heart (2006) 1.15
Importance of endothelium-derived nitric oxide in porcine coronary resistance arteries. Am J Physiol (1991) 1.15
Age-related decrease in cardiac and peripheral vascular responsiveness to isoprenaline: studies in normal subjects. Clin Sci (Lond) (1981) 1.14
Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res (1991) 1.14
Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol (1973) 1.13
5HT-kinetics and sensitivity of human blood platelets: variations with age, gender and platelet number. Thromb Haemost (1988) 1.13
A trabecular metal tibial component in total knee replacement in patients younger than 60 years: a two-year radiostereophotogrammetric analysis. J Bone Joint Surg Br (2008) 1.11
Simple renal cyst and hypertension: cause or coincidence? Clin Nephrol (1986) 1.11
The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol (1982) 1.11
Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension (1997) 1.10
Pulsatile stretch stimulates superoxide production and activates nuclear factor-kappa B in human coronary smooth muscle. Circ Res (1997) 1.09
Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation (1994) 1.08
Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul (1990) 1.08
Overexpression of connective tissue growth factor gene induces apoptosis in human aortic smooth muscle cells. Circulation (1999) 1.08
The vasodilator potency of atrial natriuretic peptide in man. Circulation (1987) 1.07
Local anesthetic drugs reduce endothelium-dependent relaxations of porcine ciliary arteries. Invest Ophthalmol Vis Sci (1993) 1.07
Normal renin secretion in hypertensive patients with primarily unilateral chronic hydronephrosis. J Urol (1974) 1.07
Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation (1997) 1.07
Enhancement of calcium influx in human platelets by CGP 28392, a novel dihydropyridine. Biochem Biophys Res Commun (1984) 1.06
Epidermal growth factor responsiveness in smooth muscle cells from hypertensive and normotensive rats. Hypertension (1989) 1.05
Captoril-associated agranulocytosis. Lancet (1980) 1.05
Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol (1973) 1.05